Abstract
Hepatitis B virus (HBV) infection is a major risk factor worldwide for the development of hepatocellular carcinoma (HCC). Integrated HBV DNA fragments, often highly rearranged, are frequently detected in HCC. In woodchuck, the viral enhancer plays a central role in hepatocarcinogenesis, but in humans the mechanism of HBV oncogenesis has not been established. In this study we investigated the status of the viral enhancer in two human HCC cell lines, Hep3B and PLC/PRF/5 each containing one or more integrated HBV DNA fragments. Active enhancer was defined by virtue of its protein occupancy as determined by genomic in vivo DMS footprinting. In PLC/PRF/5 cells, the HBV DNA was integrated in a cellular gene at chromosome 11q13, at a locus reported to be amplified in many tumors. We show here that in both cell lines, the integrated HBV DNA fragments contain an active enhancer-I. In particular, the occupation of the two previously defined basic enhancer elements, E and EP, was prominent. While in both cell lines the same protein binds to the EP elements, the E element, however, is occupied in a cell-line specific manner. In PLC/PRF/5 but not Hep3B, the prominent binding of an undefined protein was detected. Our data suggest that this protein is likely to be the fetoprotein transcription factor (FTF). The finding that enhancer sequences are conserved and functional in different cell lines suggests a selection pressure for their long-term maintenance. We therefore propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ben-Levy R, Faktor O, Berger I, Shaul Y . 1989 Mol. Cell. Biol. 9: 1804–1809
Berger I, Shaul Y . 1987 J. Virol. 61: 1180–1186
Blake M, Niklinski J, Zajac KM . 1996 J. Virol. 70: 6060–6066
Bossard P, McPherson CE, Zaret KS . 1997 Methods 11: 180–188
Bulla GA, Siddiqui A . 1988 J. Virol. 62: 1437–1441
Butel JS, Lee TH, Slagle BL . 1996 Trends Microbiol. 4: 119–124
Chami M, Gozuacik D, Saigo K, Capiod T, Falson P, Lecoeur H, Urashima T, Beckmann J, Gougeon ML, Claret M, le Maire M, Brechot C, Paterlini-Brechot P . 2000 Oncogene 19: 2877–2886
Chang HK, Chou CK, Chang C, Su TS, Hu C, Yoshida M, Ting LP . 1987 Nucleic Acids Res. 15: 2261–2268
Chen JY, Harrison TJ, Tsuei DJ, Hsu TY, Zuckerman AJ, Chan TS, Yang CS . 1994 Intervirology 37: 41–46
Datta S, Kothari NH, Fan H . 2000 J. Virol. 74: 8277–8285
Dignam JD, Lebovitz RM, Roeder RG . 1983 Nucleic Acids Res. 11: 1475–1489
Dikstein R, Faktor O, Ben-Levy R, Shaul Y . 1990a Mol. Cell. Biol. 10: 3682–3689
Dikstein R, Faktor O, Shaul Y . 1990b Mol. Cell. Biol. 10: 4427–4430
Doitsh G, Shaul Y . 1999 Oncogene 18: 7506–7513
Faktor O, Budlovsky S, Ben-Levy R, Shaul Y . 1990 J. Virol. 64: 1861–1863
Faktor O, De-Medina T, Shaul Y . 1988 Virology 162: 362–368
Flajolet M, Tiollais P, Buendia MA, Fourel G . 1998 J. Virol. 72: 6175–6180
Fourel G, Couturier J, Wei Y, Apiou F, Tiollais P, Buendia MA . 1994 EMBO J. 13: 2526–2534
Galarneau L, Pare JF, Allard D, Hamel D, Levesque L, Tugwood JD, Green S, Belanger L . 1996 Mol. Cell. Biol. 16: 3853–3865
Gilbert S, Galarneau L, Lamontagne A, Roy S, Belanger L . 2000 J. Virol. 74: 5032–5039
Graef E, Caselmann WH, Wells J, Koshy R . 1994 Oncogene 9: 81–87
Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A, Harris CC . 1997 Cancer Res. 57: 426–432
Haviv I, Vaizel D, Shaul Y . 1995 Mol. Cell. Biol. 15: 1079–1085
Hershkovitz M, Riggs AD . 1997 Methods 11: 253–263
Hildt E, Hofschneider PH . 1998 Recent Results Cancer Res. 154: 315–329
Ishida H, Ueda K, Ohkawa K, Kanazawa Y, Hosui A, Nakanishi F, Mita E, Kasahara A, Sasaki Y, Hori M, Hayashi N . 2000 J. Virol. 74: 1241–1251
Kairat A, Beerheide W, Zhou G, Tang ZY, Edler L, Schroder CH . 1999 Intervirology 42: 228–237
Katan Y, Agami R, Shaul Y . 1997 Nucleic Acids Res. 25: 3621–3628
Kioussis D, Festenstein R . 1997 Curr. Opin. Genet. Dev. 7: 614–619
Konig H . 1991 Nucleic Acids Res. 19: 3607–3611
Kosovsky MJ, Siddiqui A . 1999 Virology 259: 60–66
Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K . 1999 Hepatology 29: 1858–1862
Li M, Xie YH, Kong YY, Wu X, Zhu L, Wang Y . 1998 J. Biol. Chem. 273: 29022–29031
Miyaki M, Sato C, Sakai K, Konishi M, Tanaka K, Muraoka M, Kikuchi-Yanoshita R, Nadaoka Y, Kanda H, Kitagawa T . 2000 Int. J. Cancer 85: 518–522
Ori A, Shaul Y . 1995 Virology 207: 98–106
Ostapchuk P, Scheirle G, Hearing P . 1989 Mol. Cell. Biol. 9: 2787–2797
Ou JH, Yen TS, Wang YF, Kam WK, Rutter WJ . 1987 Nucleic Acids Res. 15: 8919–8934
Paran N, Ori A, Haviv I, Shaul Y . 2000 Mol. Cell. Biol. 20: 834–841
Rivkina M, Cote PJ, Robinson WS, Tennant BC, Marion PL . 1996 Carcinogenesis 17: 2689–2694
Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, Koyama K, Nakamura Y, Abe T, Inazawa J . 1999 Br. J. Cancer 80: 2034–2039
Shaul Y, Ben-Levy R . 1987 EMBO J. 6: 1913–1920
Shaul Y, Garcia PD, Schonberg S, Rutter WJ . 1986 J. Virol. 59: 731–734
Shaul Y, Ziemer M, Garcia PD, Crawford R, Hsu H, Valenzuela P, Rutter WJ . 1984 J. Virol. 51: 776–787
Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, Park NH, Colicelli J, Gollin SM . 2000 Genes Chromosomes Cancer 28: 153–163
Siegrist CA, Durand B, Emery P, David E, Hearing P, Mach B, Reith W . 1993 Mol. Cell. Biol. 13: 6375–6384
Wang P, Ka-Wai Hui E, Chiu J, Lo SJ . 2001 J. Virol. Methods 92: 83–90
Wong N, Lai P, Pang E, Fung LF, Sheng Z, Wong V, Wang W, Hayashi Y, Perlman E, Yuna S, Lau JW, Johnson PJ . 2000 Clin. Cancer Res. 6: 4000–4009
Zhou DX, Yen TS . 1990 J. Biol. Chem. 265: 20731–20734
Ziemer M, Garcia P, Shaul Y, Rutter WJ . 1985 J. Virol. 53: 885–892
Acknowledgements
We thank S Budilovsky for excellent assistance. This research was supported by MINERVA Foundation, Germany. Y Shaul holds the Oscar and Emma Getz Professorial chair.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shamay, M., Agami, R. & Shaul, Y. HBV integrants of hepatocellular carcinoma cell lines contain an active enhancer. Oncogene 20, 6811–6819 (2001). https://doi.org/10.1038/sj.onc.1204879
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204879